Compare IPDN & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the Professional Diversity Network (PDN) segment, which includes online professional networking communities with career resources for diverse cultural groups and employers looking to hire members; and the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization, the RemoteMore segment. The company generates majority of its revenue from PDN Segment.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.